SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines
about
4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression.SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancerAdvancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format.Current challenges for cancer vaccine adjuvant development.
P2860
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines
@ast
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines
@en
type
label
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines
@ast
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines
@en
prefLabel
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines
@ast
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines
@en
P2093
P2860
P1476
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines
@en
P2093
Esma S Yolcu
Haval Shirwan
Rajesh K Sharma
P2860
P304
P356
10.1586/14760584.2014.880340
P577
2014-03-01T00:00:00Z